Herein a new relaxometric method to assess intestinal permeability based on the oral administration of clinically approved Gd-based MRI contrast agents (CAs) is proposed.
Introduction
The ability of intestinal epithelium to function as a barrier between the external environment and the closely regulated internal domain is essential for human health.
The disruption of this barrier system results in a "leaky" intestine. Increased intestinal permeability is associated with several diseases including Inflammatory Bowel Diseases (IBD) (1), Irritable Bowel Syndrome (IBS) (2, 3) , Celiac Disease (4), Crohn's Disease (5) and food allergy.
Along the years, several methods have been tested for assessing changes in the intestinal microvasculature associated to the presence of inflammatory processes, such as the use of fiberoptic confocal imaging (6) , or the rotational side-view confocal endomicroscopy (7) or DCE-MRI colonography (8) . The intestinal inflammation is invariantly accompanied by lesions in the intestinal epithelium which lead to an increase in the intestinal permeability. Often, Intestinal Permeability Tests (IPTs), based on the oral ingestion of molecules that cannot be metabolized, are used. By this approach, the extent of urine excretion of these molecules is taken as reporter to detect intestinal dysfunction (9, 10) .
IPTs are based on the differential intestinal absorption of two inert molecular probes (of different size) that are administered orally. Urine is typically collected 6-12 h after the oral administration of the probes in order to assess their eventual release through the leaky intestine and their subsequent renal excretion via the blood circulation. Small probes (the most used are Mannitol (M) or Rhamnose ( R) (MW 182 Da for both)) are thought to cross the intestinal barrier freely. A second, larger probe, usually a disaccharide such as Lactulose (L) (MW 342 Da), permeates only when the barrier 4 integrity is lost but it is affected in the same way as the small probe by the pre-and post-mucosal confounders. The ratio between the amounts of disaccharide and monosaccharide (L/M) in urine is thus considered as a reporter of the loss of intestinal barrier function. For the study of colonic permeability, urine has to be collected for a time longer than 6 hours and the used probes have to be well resistant to the attack of colonic bacteria. Among the sugar-based probes, Sucralose (S) (MW 397.6 Da), which is a chlorinated derivative of sucrose, appears to pass through all the digestive tract unaltered and so it has been proposed a sensitive reporter of damages along all the intestinal tract (11, 12) . The amount of the sugar-based probes present in the urine has been measured by several methods, namely, enzyme assays, high performance liquid chromatography (HPLC), liquid chromatography in combination with mass spectrometry and Pulsed Amperometric Detection (13).
Other intestinal permeability tests include the absorption/excretion of 51 Cr-EDTA (14, 15) , 51 Cr-EDTA/ 14 C-Mannitol excretion ratio (16) , polyethylene glycol (17) and Dxylose (18), X-ray contrast media (19, 20) , but the gold standard, for small bowel diseases, remains the L/M test.
Herein, a new method based on the oral administration (and urine detection) of clinically approved Gd-based MRI contrast agents is proposed. The Gd(III)-complexes here investigated (Gd-HPDO3A, Gd-DTPA and Gd-BOPTA) are actually extensively used in the clinical practice as MRI contrast agents because they markedly enhance the water proton relaxation rate of tissue water protons (21) . In recent years, contrast enhanced MRI has also emerged as a useful modality for enterography and colonography, both in clinical and preclinical research, to monitor inflammation in IBD (22, 23) and in colon cancer (24, 25) . Moreover, the intravenous injection of a macromolecular contrast agent, based on the Albumin-GdDTPA conjugate, has been used to report on changes in vascular permeability in murine colitis models (8) .
The quantitative detection of the Gd-based probes in urine relies on a method that is very easy to implement because the paramagnetism of the Gd 3+ ions causes a decrease of the water proton relaxation time (T1), that is proportional to the concentration of the agent (26) . The measure of the longitudinal relaxation rate (R1obs = 1/T1obs) can be carried out on any NMR spectrometer with a semiautomatic procedure which requires from 1 to 5 minutes depending on the concentration of the paramagnetic probe in urine.
As no sample preparation nor external calibration is required, the T1-based method results in a much faster procedure with respect to the "gold standard" HPLC or HPLC/MS analysis. The Gd-complexes are relatively large molecules (MW 500-1000 Da), highly hydrophilic and are not degraded by the colon bacteria, so they appear excellent candidates to report on membrane damages along all the intestinal tract.
The method has been tested on a murine model of colitis induced through the administration of Dextran Sulfate Sodium (DSS) in the drinking water to BALB/c mice (27) . In this model, in which small intestine's permeability is not altered, an increase in the urinary concentration of the Gd-based probes is considered indicative of enhanced colonic permeability. Colitis was induced in six-week-old male mice (20-25 g body weight) by addition of 3% DSS (w/v, final concentration, MP Biomedicals, MW 35,000-50,000 Da) to their drinking water for 5 days, followed by 4 days with normal drinking water, as described previously (27) . Mice were daily assessed for colitis symptoms. The clinical course of the disease was represented by a colitis clinical score (28) , that was determined as the sum of the scores assigned for the following items: i) body weight loss (0, none; 1, 1-5%; 2, 5-10%; 3, 10-20%; 4, more than 20%), ii) stool consistency (0, well formed pellets; 2, pasty and semiformed stools; 4, liquid stools), and iii) the presence or absence of fecal blood (0, negative; 2, light bleeding; 4, marked bleeding). Accordingly, the score can range from 0 (healthy) to 12 (maximal colitis activity). At day 9 from the beginning of DSS treatment, animals were sacrificed, colons removed and their length measured from the anus to the beginning of caecum, as an indirect marker of inflammation. Colons were then prepared as Swiss rolls (28) , fixed in 4% buffered formaldehyde and subsequently embedded in paraffin for histopathological analysis of H&E stained-sections.
Study design
The study design is schematically illustrated in scheme 1.
A pilot experiment was set up to assess whether the proposed methodology yields results consistent with the established sugar based method.
Mice (n=10 per group), including colitis and controls, were fed overnight with iron/manganese-free diet and administered with an oral dose (200 µl) consisting of ProHance ® (4.56 µmoles) and a mix of sugars (Lactulose 0.0584 mmoles, Mannitol 0.11 mmoles and Sucralose 0.0503 mmoles) at day 3 after the beginning of DSS treatment. Urine was then collected, by using proper metabolic cages which allow for a continuous urine collection (avoiding interferences with stool), for 24 h in two slots, i.e. over the first 0-6h and the successive 6-24h, respectively. On the assumption that renal excretion is fast (ca. 30 min), the chosen time slots allow to evaluate the permeability within small (0-6h) and large (6-24h) intestine, respectively (29) (30) (31) . Total volumes of collected urines were recorded and 1ml from each slot was stored at -20°C until used for ICP-MS (for the determination of Gd content) and HPLC-MS (for the determination of sugars content) analyses.
Next, in the second study, ProHance ® has been compared with two other established MRI contrast agents (MultiHance ® and Magnevist ® ) by applying the relaxometric methodology.
At days 3 and 8 after starting the DSS treatment, as above, all mice (n=5 per group), including colitis and controls, were orally administered with a bolus (120 µl) of water solutions of ProHance ® , MultiHance ® or Magnevist ® (4.56 µmoles), respectively. The urine collection was carried out for 0-6h and 6-24h, as described above. Individual volumes of collected urines over each time interval were recorded and the longitudinal relaxation rates were measured. ICP-MS analysis for the determination of the total Gd urinary excretion was carried out only on the overall 24h collection for each mouse. collections.
Relaxometric analysis of urines and Gd content determination

Statistical analysis
Data are represented as mean±SD. Comparison between groups was carried out by using an unpaired data Student's t-test. Differences between groups were considered significant at 95% (*) with P< 0.05, at 99% (**) with P < 0.01 and at 99.9% (***) with P < 0.001.
Results and Discussion
Colitis Model and damage assessment
Mice were subjected to DSS-induced colitis as described in the Experimental section.
Control mice received regular drinking water. The extent of DSS-induced colitis was judged by various parameters, such as clinical score, colon length and histological features. All mice exposed to the DSS treatment displayed a consistently high clinical score, assessed by weight loss, stool consistency and bleeding as described in the Experimental section (Table 2 ). In addition, all DSS-treated mice showed a significant shortening of the colon length with respect to their healthy controls; this item is considered an important inflammation index. The lowest clinical score (score = 1) assigned to control mice is due to a slight weight loss as a consequence of the administered iron/manganese-free diet. Histological analysis of the colon sections from DSS-treated mice showed typical inflammatory alterations in the colon architecture, such as ulcerations, surface epithelial loss, crypt destruction and abundant inflammatory infiltrate ( Figure 2 ).
Validation of the use of the Gd-based complexes as intestinal permeability probes vs the established sugars-based method
The herein proposed method consists of the oral administration of paramagnetic Small intestine damages have been traditionally evaluated through the measure of L/M ratio, while Sucralose, a chlorinated sucrose molecule which is considered to pass through all the digestive tract unaltered, has been used to measure permeability alterations in the colonic tract (11) . Inspection into the data reported in Figure 3 shows that the results obtained from the two sets of measurements are in very good agreement (correlation significant at 99% in Fig 3D) , both underlying a highly significant difference between healthy and colitis mice in the 6-24h urine collections. Moreover, in the 0-6h urine samples, which are investigated to report on alterations in the small intestine, no significant difference has been observed between healthy and treated mice both with the sugars mix and with the Gd-based method. The damage inferred through the administration of DSS is in fact at the level of the colon tract (28) .
Set-up of the 1 H-relaxometric method
Once demonstrated that the use of ProHance ® provides a reliable assessment of colon found, which is slightly higher than the value measured in water (32) . This finding can be accounted for the small increase in the viscosity but it rules out the occurrence of any significative interaction of the paramagnetic probe with urine components which, at the applied magnetic field, would markedly increase its relaxivity with respect to neat water solutions.
It was deemed interesting to compare ProHance ® with two other Gd-based MRI CAs Figure 1 ). While Prohance ® and Magnevist ® are highly hydrophilic molecules with a rapid renal excretion, MultiHance ® is functionalized with an hydrophobic benzyl-oxymethyl substituent that promotes its interaction with serum-albumin and consequently drives its marked hepatic transit (33, 34) . Pavone et al. (35) showed that MultiHance ® undergoes biliary (39%) as well as renal (55%) excretion. Thus, also in the presence of intestinal leakage, MultiHance ® is only partially recovered in urines, as the renal excretion represents only 55% of the total excreted amount. 15 At day 8-9, when the damage was in the "repair" stage, the observed increase of Gdcomplexes in the urine does not appear to be significant with respect to that observed in healthy mice for all tested MRI contrast agents.
As a general remark, it is interesting to note that the three CAs have a very similar renal excretion in healthy mice. the colon morphology (data not shown) were comparable between DSS-treated mice with or without CA administration. Figure 5 reports the observed relaxation rates (R1obs) data for the 0-6h and 6-24h urine collections for the three CAs. To account for the differences in urine volumes, the observed relaxation rates have been multiplied for the total urine volume. In accordance with the excretion values reported in Figure 4 , the relaxation enhancement of urines of mice in the severe stage of colitis is 2.6 and 2.7 fold that of control mice for ProHance ® and Magnevist ® , while the difference decreases significantly in the repairing stage. The results obtained with MultiHance ® confirm those ones reported in Fig. 4 , as the values obtained for colitis mice were not significantly different from those of control mice.
In vivo MRI experiments were carried out on control and DSS treated mice, at day 4 and 8 after the start of DSS treatment, to assess the kidney and liver distribution of the paramagnetic ProHance® orally administered at 0.015 mmol/Kg dose (see Supp. Info. -Fig. S3 ). 16 The increased urinary excretion of ProHance® in DSS treated mice in the acute phase of the damage (day 4) is accompanied by an increased MR-signal enhancement in kidneys but not in liver ( Supplementary Material Fig.S3 ). 24 hours after the ingestion of the probe, a significantly higher (P= 0.04 with respect to control mice) MR-signal enhancement in kidneys was found in the acute phase of DSS damage but not in the recovery stage.
As expected, this neutral and hydrophilic contrast agent has a rapid renal elimination and therefore the portion of the orally administered dose that escapes the leaky intestinal barrier enters the blood circulation from which it is eliminated through the kidneys.
Concluding remarks
The amounts of ProHance ® and Magnevist ® orally administered and recovered in the urine of mice with DSS-induced colitis are significantly enhanced and parallel the behavior of the currently used sugar-based intestinal permeability probes. While the actual mechanism(s) for the increased urinary excretion of an orally administered probe in colitis mice remains undetermined and may involve multiple factors, it appears associated to an increased escape from the intestinal barrier, so ProHance ® and Magnevist ® can be considered good probes to assess changes in intestinal permeability.
In principle, the highly hydrophilic Gd-HPDO3A and Gd-DTPA complexes have an analogous behavior of the radioactive 51 Cr-EDTA (36) and 99m Tc-DTPA (37, 38) complexes, but their use could be considered preferable in terms of the higher safety.
On the contrary, MultiHance ® did not result to be a good intestinal permeability probe as its partial hepato-biliary elimination reduces its urinary recovery.
The main advantage of the herein proposed method relies on the fact that the quantitative detection of Gd-based probes in urine is straightforward because their paramagnetism causes a marked decrease of the water proton relaxation time (T1). This effect is largely exploited in the clinical use of these Gd-containing agents as they yield a dramatic increase in the MR signal of the tissues where they distribute. The measurement of the longitudinal relaxation time of water protons is routinely accessible on any NMR spectrometer. Actually, when one is only interested to acquire the strong and cheap relaxometers that can eventually be made available on the desk of doctor's offices or in pharmacy shops. 
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